23000-12-6

Basic information

• Product Name: Ethanone, 1-(2,5-dimethyl-4-oxazolyl)- (9CI)
• Synonyms: Ethanone, 1-(2,5-dimethyl-4-oxazolyl)- (9CI);1-(2,5-Dimethyl-4-Oxazolyl) Ethanone;Ethanone, 1-(2,5-dimethyl-4-oxazolyl)-;1-(2,5-DiMethyloxazol-4-yl)ethanone
• CAS NO: 23000-12-6
• Molecular Formula: C₇H₉NO₂
• Molecular Weight: 139.15186
• Product Categories: ACETYLGROUP
• Mol File: 23000-12-6.mol
• Article Data: 4

Chemical Properties

• Melting Point: 49 °C
• Boiling Point: 203.678 °C at 760 mmHg
• Flash Point: 76.982 °C
• Appearance: /
• Density: 1.074 g/cm³
• Vapor Pressure: 0.274mmHg at 25°C
• Refractive Index: 1.473
• Storage Temp.: 2-8°C
• PKA: 0.11±0.10(Predicted)
• CAS DataBase Reference: Ethanone, 1-(2,5-dimethyl-4-oxazolyl)- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Ethanone, 1-(2,5-dimethyl-4-oxazolyl)- (9CI)(23000-12-6)
• EPA Substance Registry System: Ethanone, 1-(2,5-dimethyl-4-oxazolyl)- (9CI)(23000-12-6)

Safety Data

• Hazardous Substances Data: 23000-12-6(Hazardous Substances Data)

Usage

General Description

Ethanone, 1-(2,5-dimethyl-4-oxazolyl)- (9CI) is a chemical compound with the molecular formula C7H9NO2. It is a derivative of ethanone (also known as acetone) and contains a 2,5-dimethyl-4-oxazolyl group. Ethanone, 1-(2,5-dimethyl-4-oxazolyl)- (9CI) has potential applications in pharmaceuticals, agrochemicals, and materials science. Its specific properties and potential uses may depend on its reactivity, solubility, and other physical and chemical characteristics, which have yet to be fully determined. Further research and testing may be needed to fully understand and utilize the properties of this chemical compound.

InChI:InChI=1/C7H9NO2/c1-4(9)7-5(2)10-6(3)8-7/h1-3H3

Upstream product

• 108-24-7 acetic anhydride 
• 29917-12-2 Isonitrosoacetylacetone 
• 92901-88-7 2,5-Dimethyl-4-oxazolecarboxaldehyde 
• 940879-48-1 1-(2,5-dimethyloxazol-4-yl)ethanol 
• 75-05-8 acetonitrile 
• 123-54-6 acetylacetone 
• 5440-23-3 3-(acetylamino)-2,4-pentanedione 
• 127916-14-7 1-((3aR,3bS,6aS,6bR)-3b-Acetyl-2,5,6a,6b-tetramethyl-6a,6b-dihydro-3bH-1,6-dioxa-3,4-diaza-cyclobutadicyclopenten-3a-yl)-ethanone 
• 127916-13-6 1-(2-Acetyl-3-methyl-2H-azirin-2-yl)-ethanone 
• 35166-20-2 1-(3,5-dimethyl-1,2-oxazol-4-yl)ethanone 

Downstream Products

• 103793-55-1 4-[2-(2,5-Dimethyl-4-oxazolyl)-2-hydroxyethoxy]aniline 
• 103789-10-2 4-(4-Acetamidophenoxyacetyl)-2,5-dimethyloxazole 
• 103789-11-3 4-[2-(2,5-Dimethyl-4-oxazolyl)-2-hydroxyethoxy]acetanilide 
• 103788-33-6 5-{4-[2-(2,5-dimethyl-4-oxazolyl)-2-oxoethoxy]benzyl}-2,4-thiazolidinedione 
• 103788-11-0 5-{4-[2-(2,5-dimethyl-4-oxazolyl)-2-hydroxyethoxy]benzyl}-2,4-thiazolidinedione 
• 103789-12-4 5-{4-[2-(2,5-Dimethyl-oxazol-4-yl)-2-hydroxy-ethoxy]-benzyl}-2-imino-thiazolidin-4-one 
• 1616100-72-1 (R)-N-((2S,4R)-2-(2,4-difluoro-5-(pyrimidin-5-yl)phenyl)-4-(2,5-dimethyloxazol-4-yl)-4-hydroxybutan-2-yl)-2-methylpropane-2-sulfinamide 
• 1616100-73-2 (1R,3S)-3-amino-3-(2,4-difluoro-5-(pyrimidin-5-yl)phenyl)-1-(2,5-dimethyloxazol-4-yl)butan-1-ol 
• 1616100-74-3 N-(((2S,4R)-2-(2,4-difluoro-5-(pyrimidin-5-yl)phenyl)-4-(2,5-dimethyloxazol-4-yl)-4-hydroxybutan-2-yl)carbamothioyl)benzamide 
• 1616100-25-4 (4S,6S)-4-(2,4-difluoro-5-(pyrimidin-5-yl)phenyl)-6-(2,5-dimethylisoxazol-4-yl)-4-methyl-5,6-dihydro-4H-1,3-thiazin-2-amine 
• 1616101-01-9 (4S,6R)-4-(2,4-difluoro-5-(pyrimidin-5-yl)phenyl)-6-(2,5-dimethylisoxazol-4-yl)-4-methyl-5,6-dihydro-4H-1,3-thiazin-2-amine 
• 1616100-71-0 (R)-N-((S)-2-(2,4-difluoro-5-(pyrimidin-5-yl)phenyl)-4-(2,5-dimethyloxazol-4-yl)-4-oxobutan-2-yl)-2-methylpropane-2-sulfinamide 
• 13788-01-7 4-[2-(2,5-dimethyl-oxazol-4-yl)-2-oxo-ethylideneamino]-benzenesulfonamide 
• 13917-23-2 4-[2-(2,5-dimethyl-oxazol-4-yl)-2-oxo-ethylideneamino]-benzoic acid 

Relevant articles and documents

4,6-DIARYLAMINOTHIAZINES AS BACE1 INHIBITORS AND THEIR USE FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION

Compounds of formula (I), including pharmaceutically acceptable salts thereof, are set forth herein: (I) wherein R1 and R2 are independently hydrogen, or -CH3; or R1 and R2 can join together in a ring by adding -(CH2)4-; R3 is hydrogen or C1-C3 al-kyl; Y and Z are independently a C6-C10- aryl group or a 5-10 membered heterocyclic group which can be further substituted with from 0-3 substituents selected from the group of halogen, hydroxy, amino, C1-4 alkylamino, C1-4 dialkylamino, halo C1-4 alkyl, CN, C1-C6, alkyl or cycloalkyl, C1-C6 alkoxy, -C=OC1-4 alkyl, -SO2C1-4 alkyl, and C2-C4 alkynyl; A is selected from the group of phenyl, ben-zyl, oxazolyl, thiazolyl, isoxazolyl, imidazolyl, pyrazolyl, pyridyl, pyrimidinyl, and pyrazinyl groups which can be further substituted with from 0-3 substituents selected from the group of halogen, hydroxy, amino, C1-4 alkylamino, C1-4 dialkylamino, haloC1-4 alkyl, hydroxyC1-6 alkyl, CN, C1-C6 alkyl or cycloalkyl, C1-C6 alkoxy, and C2-C4 alkynyl; L is -NHCO-, or is a single bond; and L and Z to-gether can be absent

Studies on antidiabetic agents. 11. Novel thiazolidinedione derivatives as potent hypoglycemic and hypolipidemic agents

In the course of further chemical modification of the novel antidiabetic pioglitazone (AD-4833, U-72, 107), a series of 5-[4-(2- or 4- azolylalkoxy)benzyl- or -benzylidene]-2,4-thiazolidinediones was prepared and evaluated for hypoglycemic and hypolipidemic activities in insulin-resistant, genetically obese, and diabetic KKA(y) mice. Replacement of the 2-pyridyl moiety of pioglitazone by a 2- or 4-oxazolyl or a 2- or 4-thiazolyl moiety greatly enhanced in vivo potency. The corresponding 5-benzylidene-type compounds, in which a methine was used as a linker between the benzene ring and the thiazolidinedione ring, also had potent biological activity. Among the compounds synthesized, 5-[4-[2-(5-methyl-2-phenyl-4- oxazolyl)ethoxy]benzyl]-2,4-thiazolidinedione (18) exhibited the most potent activity, more than 100 times that of pioglitazone. The synthesis and structure-activity relationships for this novel series of derivatives are detailed.